61
Registered trials
30
Recruiting
26
Completed trials
44
Sponsors
23
Countries
Phase III:
17
Phase II/III:
6
Phase II:
13
Phase I/II:
4
Phase III/IV:
1
Phase IV:
18
Phase I (FiH):
2
Oversight events:
2 serious breaches
5 temporary halts
1 urgent safety measure
1 unexpected event
3 corrective measures
across 6 trials
View oversight register →
Indications tested
Dermatitis atopic
7
Kidney transplant rejection
3
Pancreas transplant
1
Type 1 diabetes mellitus
1
Myasthenia gravis
1
Systemic lupus erythematosus
1
Interstitial lung disease
1
Renal transplant
1
Immune-mediated myositis
1
Lupus nephritis
1
Progressive multiple sclerosis
1
End stage renal disease
1
Sponsors using this IMP
Centre Hospitalier Universitaire De Nantes
5
Sanofi-Aventis Recherche & Developpement
5
Novartis Pharma AG
3
Oslo University Hospital HF
3
Centre Hospitalier Universitaire Rouen
2
Charite Universitaetsmedizin Berlin KöR
2
Eledon Pharmaceuticals Inc.
2
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
2
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
2
Universitair Medisch Centrum Groningen
2
AbbVie Deutschland GmbH & Co. KG
1
Amsterdam UMC Stichting
1
All trials — page 3
61 totalShowing 49–61 of 61 trials